"サノフィ" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonSanofi's oral TNF inhibitor misses mark in phase 2 psoriasis trial, prompting focus on combos - F...
Sanofi's oral TNF inhibitor misses mark in phase 2 psoriasis trial, prompting focus on combos Fierce Biotech
Sanofi and Regeneron's high-flying Dupixent on course for an 'inflection year' in COPD - Fierce P...
Sanofi and Regeneron's high-flying Dupixent on course for an 'inflection year' in COPD Fierce Pharma
European pharma companies push for higher drug prices in EU amid U.S. tariff threats - Reuters
European pharma companies push for higher drug prices in EU amid U.S. tariff threats Reuters
Sanofi's Altuviiio closing in on blockbuster status, Dupixent sales surge - Endpoints News
Sanofi's Altuviiio closing in on blockbuster status, Dupixent sales surge Endpoints News
€15M Sanofi Investment Powers Innate Pharma's Pipeline Growth: Key Partnership Expands - Stock Titan
€15M Sanofi Investment Powers Innate Pharma's Pipeline Growth: Key Partnership Expands Stock Titan
and Announces Sanofi’s Intention to Make a Strategic Investment in the Company - Business Wire
and Announces Sanofi’s Intention to Make a Strategic Investment in the Company Business Wire
Novartis-, Sanofi-Backed Granite Brings $100M to Compete in Crowded I&I Space - BioSpace
Novartis-, Sanofi-Backed Granite Brings $100M to Compete in Crowded I&I Space BioSpace
Sanofi stays on course amid tariff turmoil - BioPharma Dive
Sanofi stays on course amid tariff turmoil BioPharma Dive
Dupixent and new launches lift Sanofi - The Pharma Letter
Dupixent and new launches lift Sanofi The Pharma Letter
Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail - Clinical T...
Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail Clinical Trials Arena
Sanofi's quarterly profit boosted by Dupixent and newer drugs; forecast unchanged - Reuters
Sanofi's quarterly profit boosted by Dupixent and newer drugs; forecast unchanged Reuters
Dupixent sales continue to grow as Altuviiio set to become Sanofi's next blockbuster - FirstWord ...
Dupixent sales continue to grow as Altuviiio set to become Sanofi's next blockbuster FirstWord Pharma
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed - GlobeNewswire
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed GlobeNewswire
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug - WSJ
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug WSJ
Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe - insights.citeline.com
Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe insights.citeline.com
Sanofi Q1 Results Climb; Confirms FY25 Outlook - Nasdaq
Sanofi stock, Roche stock flat after earnings (SNY:NASDAQ) - Seeking Alpha
Sanofi stock, Roche stock flat after earnings (SNY:NASDAQ) Seeking Alpha
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit - ...
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit Benzinga
Sanofi hands back cancer NK cell engager to Innate amid autoimmune pivot - Fierce Biotech
Sanofi hands back cancer NK cell engager to Innate amid autoimmune pivot Fierce Biotech
Innate Pharma Announces €15M Investment by Sanofi - Business Wire
Innate Pharma Announces €15M Investment by Sanofi Business Wire
Sanofi, Novartis CEOs lambast EU price control as Trump reportedly weighs drug cost parity with o...
Sanofi, Novartis CEOs lambast EU price control as Trump reportedly weighs drug cost parity with other nations Fierce Pharma
Spotlight On: What Sanofi said on its Q1 earnings call… - FirstWord Pharma
Spotlight On: What Sanofi said on its Q1 earnings call… FirstWord Pharma
Following Rejection, FDA Okays Sanofi/Regeneron’s Dupixent for Chronic Hives - BioSpace
Following Rejection, FDA Okays Sanofi/Regeneron’s Dupixent for Chronic Hives BioSpace
Sanofi Reports Strong Q1 2025 Performance and Confirms Guidance - TipRanks
Sanofi Reports Strong Q1 2025 Performance and Confirms Guidance TipRanks
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth - TradingView
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth TradingView
Blockbuster Sanofi & Regeneron Drug Dupixent Notches FDA Nod for an Inflammatory Skin Disease - M...
Blockbuster Sanofi & Regeneron Drug Dupixent Notches FDA Nod for an Inflammatory Skin Disease MedCity News
FDA approves blockbuster Dupixent for chronic hives - statnews.com
FDA approves blockbuster Dupixent for chronic hives statnews.com
Sanofi (SAN) Posts Strong Earnings as Dupixent Demand Keeps Growing - Bloomberg.com
Sanofi (SAN) Posts Strong Earnings as Dupixent Demand Keeps Growing Bloomberg.com
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition - Reuters
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition Reuters
Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs - Yahoo Finance
Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs Yahoo Finance
Changes to Innate Pharma and Sanofi ANKET collaboration - The Pharma Letter
Changes to Innate Pharma and Sanofi ANKET collaboration The Pharma Letter
Chrissy Teigen Joins Sanofi Campaign for Early Diabetes Testing - Pharmaceutical Executive
Chrissy Teigen Joins Sanofi Campaign for Early Diabetes Testing Pharmaceutical Executive
Sanofi and Regeneron’s dupilumab approved by FDA for urticaria - Pharmaceutical Technology
Sanofi and Regeneron’s dupilumab approved by FDA for urticaria Pharmaceutical Technology
Innate Pharma Secures €15 Million Investment from Sanofi - TipRanks
Innate Pharma Secures €15 Million Investment from Sanofi TipRanks
Sanofi, Regeneron score their 7th indication for Dupixent with FDA nod to treat hives condition -...
Sanofi, Regeneron score their 7th indication for Dupixent with FDA nod to treat hives condition Fierce Pharma
Sanofi’s $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II - BioSpace
Sanofi’s $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II BioSpace
Regeneron, Sanofi announce FDA approval of Dupixent for CSU - Yahoo Finance
Regeneron, Sanofi announce FDA approval of Dupixent for CSU Yahoo Finance
Sanofi (SNY) Surpasses Q1 Sales Estimates with Strong Dupixent Performance - GuruFocus
Sanofi (SNY) Surpasses Q1 Sales Estimates with Strong Dupixent Performance GuruFocus
Innate Pharma, Sanofi Finalize Investment - marketscreener.com
Innate Pharma, Sanofi Finalize Investment marketscreener.com
Sanofi (SNY) and Vaccine Makers Unfazed by Funding Cuts - GuruFocus
Sanofi (SNY) and Vaccine Makers Unfazed by Funding Cuts GuruFocus
Roche Shifts Drug Production to Sidestep Potential Tariffs - Bloomberg.com
Roche Shifts Drug Production to Sidestep Potential Tariffs Bloomberg.com
Sanofi ADR earnings beat by $0.12, revenue fell short of estimates - Investing.com
Sanofi ADR earnings beat by $0.12, revenue fell short of estimates Investing.com
Amgen, Sanofi & Novartis Drive Multiple Myeloma Market Amid US Tariff Dynamics - openPR.com
Amgen, Sanofi & Novartis Drive Multiple Myeloma Market Amid US Tariff Dynamics openPR.com
Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology - Fie...
Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology Fierce Biotech
Meet our A Million Conversations Advisory Group - Sanofi
Sanofi SA reports results for the quarter ended March 31 - Earnings Summary - TradingView
Sanofi SA reports results for the quarter ended March 31 - Earnings Summary TradingView
Sanofi/Regeneron’s Dupixent granted FDA approval for chronic spontaneous urticaria - PMLiVE
Sanofi/Regeneron’s Dupixent granted FDA approval for chronic spontaneous urticaria PMLiVE
Sanofi, Regeneron win FDA nod for Dupixent in chronic hives - BioPharma Dive
Sanofi, Regeneron win FDA nod for Dupixent in chronic hives BioPharma Dive
Sanofi (SNY) Reports Strong Performance with Q1 Growth and New Approvals | SNY Stock News - GuruF...
Sanofi (SNY) Reports Strong Performance with Q1 Growth and New Approvals | SNY Stock News GuruFocus
Sanofi (SNY) Projects Strong Sales Growth and Share Buyback in 2025 | SNY Stock News - GuruFocus
Sanofi (SNY) Projects Strong Sales Growth and Share Buyback in 2025 | SNY Stock News GuruFocus
Sanofi's Dupixent gets FDA nod for chronic hives indication - Pharmaphorum
Sanofi's Dupixent gets FDA nod for chronic hives indication Pharmaphorum
FDA Action Alert: Regeneron, Sanofi and Abeona - BioSpace
Sustainability: Building a Healthier World - Sanofi
Sanofi and Sobi extend their partnership with the World Federation of Hemophilia Humanitarian Aid...
Sanofi and Sobi extend their partnership with the World Federation of Hemophilia Humanitarian Aid Program The Manila Times
Sanofi's quarterly profit boosted by Dupixent and newer drugs; forecast unchanged - MSN
Sanofi's quarterly profit boosted by Dupixent and newer drugs; forecast unchanged MSN
Sanofi, Regeneron’s Dupixent granted FDA approval to treat CSU - World Pharmaceutical Frontiers
Sanofi, Regeneron’s Dupixent granted FDA approval to treat CSU World Pharmaceutical Frontiers
Environmental Impact and Healthcare Systems’ Resilience - Sanofi
Environmental Impact and Healthcare Systems’ Resilience Sanofi
Sustainable and Equitable Access to Healthcare - Sanofi
Press Release: Sanofi’s respiratory pipeline advances with - GlobeNewswire
Press Release: Sanofi’s respiratory pipeline advances with GlobeNewswire
Innate Pharma (IPHA) Secures EUR 15M Investment from Sanofi | IPHA Stock News - GuruFocus
Innate Pharma (IPHA) Secures EUR 15M Investment from Sanofi | IPHA Stock News GuruFocus
Sanofi's high hopes for $1.1B Kymab anti-inflammatory drug dented after phase 2 asthma failure - ...
Sanofi's high hopes for $1.1B Kymab anti-inflammatory drug dented after phase 2 asthma failure Fierce Biotech
Novartis, Sanofi CEOs Say EU Should Hike Drug Prices to Boost Innovation - marketscreener.com
Novartis, Sanofi CEOs Say EU Should Hike Drug Prices to Boost Innovation marketscreener.com
Sanofi (SNY) Surpasses Q1 Revenue Expectations; Strong Pharma and Vaccine Sales Drive Growth - Gu...
Sanofi (SNY) Surpasses Q1 Revenue Expectations; Strong Pharma and Vaccine Sales Drive Growth GuruFocus
Sanofi Q1 sales up 9.7%, EPS rises 17% on Dupixent and new drug growth - Investing.com
Sanofi Q1 sales up 9.7%, EPS rises 17% on Dupixent and new drug growth Investing.com
Sanofi's Profit Outdoes Projections Thanks To Dupixent Success - Finimize
Sanofi's Profit Outdoes Projections Thanks To Dupixent Success Finimize
Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs - MSN
Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs MSN
Innate Pharma Announces €15M Investment by Sanofi | IPHA Stock News - GuruFocus
Innate Pharma Announces €15M Investment by Sanofi | IPHA Stock News GuruFocus
Sanofi: Q1 EPS up 17% - marketscreener.com
Sanofi: Q1 EPS up 17% marketscreener.com
Sanofi signs up Chrissy Teigen for diabetes screening campaign - Fierce Pharma
Sanofi signs up Chrissy Teigen for diabetes screening campaign Fierce Pharma
Sanofi: Dupixent approved for CSU in US - marketscreener.com
Sanofi: Dupixent approved for CSU in US marketscreener.com
Novartis and Sanofi call for higher drug prices in Europe - SWI swissinfo.ch
Novartis and Sanofi call for higher drug prices in Europe SWI swissinfo.ch
Sanofi Shares Hit by Currency Headwinds Despite Strong Results - marketscreener.com
Sanofi Shares Hit by Currency Headwinds Despite Strong Results marketscreener.com
Sanofi licenses immune disease drugs from startup Earendil - BioPharma Dive
Sanofi licenses immune disease drugs from startup Earendil BioPharma Dive
Sanofi to pay $125M upfront for two immunology drugs from little-known biotech - Endpoints News
Sanofi to pay $125M upfront for two immunology drugs from little-known biotech Endpoints News
Sanofi taps Nurix for pipeline nourishment once again, picking up autoimmune degrader for $15M - ...
Sanofi taps Nurix for pipeline nourishment once again, picking up autoimmune degrader for $15M Fierce Biotech
Innate Pharma (IPHA) Restructures Agreement with Sanofi, Retains Drug Rights | IPHA Stock News - ...
Innate Pharma (IPHA) Restructures Agreement with Sanofi, Retains Drug Rights | IPHA Stock News GuruFocus
Innate Pharma Regains Rights on CD123 ANKET® and Announces Sanofi’s Strategic Investment - TipRanks
Innate Pharma Regains Rights on CD123 ANKET® and Announces Sanofi’s Strategic Investment TipRanks
Sanofi Sales, Profit Beat Expectations - marketscreener.com
Sanofi Sales, Profit Beat Expectations marketscreener.com
Sanofi and Novartis are calling for American drug prices in Europe - marketscreener.com
Sanofi and Novartis are calling for American drug prices in Europe marketscreener.com
NextGen Scholars: Shaping Future Healthcare Leaders - Sanofi
Sanofi's versatile Qfitlia scores FDA nod to enter crowded hemophilia market - Fierce Pharma
Sanofi's versatile Qfitlia scores FDA nod to enter crowded hemophilia market Fierce Pharma
Sanofi: Information concerning the total number of voting rights and shares - February 2025 - Glo...
Sanofi: Information concerning the total number of voting rights and shares - February 2025 GlobeNewswire
CEO of pharma giant Sanofi says businesses should stop ‘AI washing’ - Fortune
CEO of pharma giant Sanofi says businesses should stop ‘AI washing’ Fortune
Sanofi snags GSK's Chris Corsico to serve as global head of development - Fierce Biotech
Sanofi snags GSK's Chris Corsico to serve as global head of development Fierce Biotech
US FDA approves Sanofi's bleeding disorder therapy - Reuters
GSK’s newest neuro pact is with ABL Bio, a Sanofi-partnered South Korean biotech - Endpoints News
GSK’s newest neuro pact is with ABL Bio, a Sanofi-partnered South Korean biotech Endpoints News
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria - Zacks Investment Research
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria Zacks Investment Research
Banks Sell €7.45 Billion of Debt for CD&R Sanofi Unit Buyout - Bloomberg.com
Banks Sell €7.45 Billion of Debt for CD&R Sanofi Unit Buyout Bloomberg.com
Press Release: Sanofi to acquire Dren Bio’s bispecific - GlobeNewswire
Press Release: Sanofi to acquire Dren Bio’s bispecific GlobeNewswire
Sanofi-Regeneron’s Dupixent gets FDA’s nod for skin condition - PharmaLive
Sanofi-Regeneron’s Dupixent gets FDA’s nod for skin condition PharmaLive
Sanofi with We Are ILL, Inc. Rings the Opening Bell - Nasdaq
Is Sanofi (SNY)the Best Gene-Editing Stock to Buy? - Yahoo Finance
Is Sanofi (SNY)the Best Gene-Editing Stock to Buy? Yahoo Finance
Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Ma...
Sanofi’s Dupixent Gains FDA Approval for Chronic Spontaneous Urticaria - TipRanks
Sanofi’s Dupixent Gains FDA Approval for Chronic Spontaneous Urticaria TipRanks
French pharma group Sanofi forms $275m China drugs fund - - Global Venturing
French pharma group Sanofi forms $275m China drugs fund - Global Venturing
Sanofi’s Next-Generation Asthma Drug Disappoints in Trial - Bloomberg.com
Sanofi’s Next-Generation Asthma Drug Disappoints in Trial Bloomberg.com
Sanofi, Alnylam Win First RNAi Approval for Hemophilia A and B - BioSpace
Sanofi, Alnylam Win First RNAi Approval for Hemophilia A and B BioSpace
Driving Excellence in Biopharma: Our Formula for Success with McLaren Racing - Sanofi
Driving Excellence in Biopharma: Our Formula for Success with McLaren Racing Sanofi
Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease - BioPharma Dive
Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease BioPharma Dive
Enveda Gains Backing from Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing ...